Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size & Share 2026-2035
Report ID: GMI13777
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size
The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market was valued at USD 719 million in 2025, is estimated at USD 755 million in 2026, and is projected to reach USD 1.54 billion by 2035, growing at a 7.9% CAGR during the forecast period (2026-2035).
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Key Takeaways
Market Leader: Amgen led with over 27.8% market share in 2025.
Leading Players: Top 5 players in this market include Amgen, Novartis, CSL Behring, Grifols, Octapharma, which collectively held a market share of 64% in 2025.
The idiopathic thrombocytopenic purpura (ITP) therapeutics market encompasses ex-factory pharmaceutical revenue from treatment of immune-mediated platelet destruction across acute, persistent, and chronic disease. Demand is increasingly shaped by long-duration management of chronic disease, established use of thrombopoietin receptor agonists (TPO-RAs), and the entry of targeted oral options for patients with inadequate responses to earlier therapy.
GMI Analyst View
Based on our direct engagement with commercial decision-makers and supply-side stakeholders across the ITP treatment landscape, the global ITP therapeutics market generated revenue of approximately USD 688 million in 2024, reflecting steady demand accumulation driven by expanding chronic-ITP patient volumes and sustained TPO-RA adoption - a trajectory that sets a firm baseline for the more accelerated growth anticipated from novel oral therapy class entry and broadening geographic market access in the forecast years.
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Trends, Growth Drivers & GMI Forecast Outlook
Chronic disease management is moving treatment economics toward sequential use of differentiated mechanisms, while supply limitations in plasma-derived products and reimbursement scrutiny for premium therapies moderate the speed of mix change. The forecast depends on continued diagnosis, specialist access, and conversion of clinical innovation into funded prescribing pathways.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Chronic ITP creates recurring treatment demand because clinical response, relapse, tolerability, and treatment sequencing all influence prescribing over an extended period. TPO-RAs retain a central second-line role, while later-line use of SYK and BTK inhibitors enlarges the set of addressable patients rather than simply replacing first-line corticosteroids. This progression supports a more durable revenue base than short-course acute management.
Rilzabrutinib broadens the commercial treatment pathway by addressing immune-mediated platelet destruction through a mechanism distinct from platelet-production stimulation. Its oral administration is relevant to ambulatory care, where infusion capacity and administration burden can affect therapy selection. As reimbursement expands, targeted oral options should gain importance in refractory treatment algorithms, particularly where hematology practices can support monitoring and prior authorization.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
IVIG remains clinically consequential where rapid platelet elevation is needed, but its reliance on plasma collection and fractionation creates a supply exposure that synthetic therapies do not share. The European Medicines Agency has documented an ongoing supply shortage across the EU and EEA, attributing it in part to unexpectedly rising demand across approved uses [5]. For ITP providers, allocation pressure can disrupt acute-care planning and strengthen the case for maintenance strategies less dependent on plasma-derived supply.
Established TPO-RA treatment also creates an access hurdle for premium entrants. Payers can require patients to progress through effective existing options before funding novel targeted agents, especially in health systems using formal health technology assessment or restrictive specialty-drug formularies. That dynamic concentrates near-term novel-agent demand in refractory populations and makes reimbursement execution as important as regulatory authorization.
Diagnostic exclusion remains a practical constraint in markets with limited laboratory access and hematology capacity. Delays in confirming primary ITP or excluding secondary causes restrict the treated population even where epidemiologic need is material. Commercial expansion in emerging geographies therefore depends on patient identification, referral networks, and specialist infrastructure alongside product availability.
GMI Analyst View
We view the forecast as a test of treatment-system maturity rather than a simple measure of therapeutic innovation. Markets able to combine diagnosis, specialty prescribing, and reimbursement for oral targeted agents will capture the value of sequential care more quickly, whereas IVIG-dependent pathways and restrictive funding models will defer adoption.
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segment Analysis
By Disease Type
Chronic ITP accounted for 70.0% of the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market revenue in 2025 and is projected to generate USD 1.16 billion by 2035. Its leading position reflects sustained therapy demand across treatment lines, as patients may transition among TPO-RAs, SYK inhibitors, and newer oral agents when clinical response or tolerability changes. The chronic population is consequently the principal setting for long-duration prescription value and for adoption of treatments designed for inadequate responders.
Acute ITP is projected to hold 25.0% of market revenue by 2035 and expand at a 5.9% CAGR (2026-2035). Commercial intensity is lower because disease episodes may resolve without prolonged therapy and treatment is more concentrated in first-line corticosteroid or rapid-response IVIG use. Pediatric presentation contributes to this pattern, with conservative clinical management limiting the duration of drug exposure in many cases.
By Product Type
TPO-Receptor Agonists generated USD 374 million in 2025 and are projected to hold 48.0% of market revenue by 2035. Their position rests on established second-line use, broad clinician familiarity, and availability of oral and injectable options. Biosimilar and generic competition may constrain unit pricing in some markets, but prescription durability and multi-line treatment use preserve the category's central role.
IVIG (ITP-attributed) accounted for 24.1% of market revenue in 2025 and is projected to reach USD 277 million by 2035. It remains essential in bleeding emergencies, perioperative care, and selected pediatric settings because of its rapid platelet response. However, supply uncertainty, plasma procurement pressures, and greater confidence in maintenance-oriented alternatives are shifting the treatment mix away from routine long-term IVIG use.
Corticosteroids generated USD 58 million in 2025 and are projected to grow at a 4.7% CAGR (2026-2035). They remain entrenched as first-line therapy, yet their commercial contribution is limited by generic pricing, treatment duration, and adverse-effect considerations that restrict prolonged use. The category's role is clinical entry into treatment rather than the primary source of lifetime therapy value.
Fostamatinib / Novel Agents (BTKi) are projected to reach USD 231 million by 2035 and expand at a 20.4% CAGR (2026-2035). This trajectory reflects demand for purpose-developed options in refractory chronic ITP, where physicians need alternatives after TPO-RA failure or intolerance. Regulatory clearance for rilzabrutinib has strengthened the strategic relevance of oral immune-modulating therapies and formalized a pathway previously served more heavily by off-label treatment [2].
Others accounted for 10.8% of market revenue in 2025 and are projected to represent 13.0% by 2035. This group retains relevance where affordability, formulary restrictions, or local product availability limit access to premium therapies. Biosimilar access can sustain off-label and lower-cost treatment options, particularly in middle-income health systems where the clinically preferred and commercially accessible therapy may diverge.
By Route of Administration
Injectable (IV/SC) therapies accounted for 56.2% of market revenue in 2025 and are projected to represent 49.0% by 2035. IVIG, subcutaneous romiplostim, and intravenous rituximab retain defined roles in acute treatment and complex refractory care. Nevertheless, administration burden, infusion capacity, and the expanding availability of oral alternatives are steadily reducing the route's relative weight.
Oral therapies generated USD 315 million in 2025 and are projected to grow at a 9.6% CAGR (2026-2035). The route aligns with maintenance treatment across multiple mechanisms, including TPO-RA, SYK inhibition, BTK inhibition, and corticosteroid use. Its growth reflects patient convenience, lower dependence on infusion infrastructure, and a prescribing model increasingly centered on sustained outpatient disease control.
By Age Group
Adult patients generated USD 503 million in 2025 and are projected to account for 73.0% of market revenue by 2035. Adults represent the principal chronic-ITP treatment population and have access to the broadest range of advanced agents. Their longer treatment trajectories and greater exposure to sequential therapy support higher lifetime prescription value.
Pediatric patients accounted for 30.0% of market revenue in 2025 and are projected to grow at a 6.8% CAGR (2026-2035). Acute disease resolution and cautious prescribing narrow the long-term pharmaceutical opportunity relative to adults. IVIG and established TPO-RAs remain important, while the eventual expansion of pediatric evidence and labeling will determine the pace at which newer mechanisms participate in this segment.
By Distribution Channel
Hospital / Infusion Centers accounted for 52.0% of market revenue in 2025 and are projected to represent 44.0% by 2035. The channel remains indispensable for acute IVIG administration, complex treatment initiation, and specialist-supervised care. Its relative decline reflects migration of maintenance prescriptions toward outpatient dispensing rather than a loss of clinical relevance in urgent or high-acuity settings.
Specialty Pharmacies are projected to account for 48.0% of market revenue by 2035 and expand at a 10.4% CAGR (2026-2035). Their service model supports high-cost, long-duration oral therapies through prior-authorization coordination, adherence programs, and patient support. As targeted therapies become more common in chronic ITP, specialty dispensing becomes a strategic route for manufacturers and providers.
Retail Pharmacies generated USD 71 million in 2025 and are projected to reach USD 124 million by 2035. The channel is most relevant for generic-accessible corticosteroids and, in selected markets, oral TPO-RA dispensing. Broader generic penetration can improve patient access, although specialty channels are likely to retain the most complex and premium portions of the prescription mix.
GMI Analyst View
We see category competition, rather than competition between individual brands alone, as the defining segmentation issue. Oral targeted therapy and specialty dispensing reinforce one another, while plasma-derived and infusion-led care remain indispensable in selected settings but face a narrower role in long-term maintenance.
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Regional Analysis
North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis
The idiopathic thrombocytopenic purpura (ITP) therapeutics market in North America held 45.1% of global revenue in 2025 and is projected to grow at a 7.2% CAGR (2026-2035). The region combines advanced hematology infrastructure, broad use of TPO-RAs, and well-developed specialty-pharmacy and patient-support systems. Novel agent uptake is supported by regulatory access and specialist familiarity, although payer management continues to shape the order in which therapies are used.
United States
The United States generated USD 288 million in 2025 and is projected to reach USD 572 million by 2035. It is the primary commercial launch environment for high-value ITP therapies because specialty-drug reimbursement mechanisms, clinical trial participation, and hematology referral networks are comparatively mature. Biosimilar competition may pressure selected TPO-RA products, but demand for later-line oral agents supports continued expansion.
Canada
Canada accounted for 5.0% of global market revenue in 2025 and is projected to grow at a 7.9% CAGR (2026-2035). Provincial reimbursement structures commonly encourage stepwise therapy use, creating durable demand for established TPO-RAs before premium agents receive broad access. This makes formulary progression and health technology assessment outcomes central to the timing of novel-agent adoption.
Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis
Europe generated USD 194 million in 2025 and is projected to hold 27.1% of global market revenue by 2035. The region has mature clinical management of ITP but fragmented national reimbursement decisions, which can delay uptake of premium agents despite European authorization. The European Commission's authorization of rilzabrutinib creates a new therapeutic option, while country-level funding negotiations will determine its commercial pace [6].
Germany
Germany generated USD 40 million in 2025 and is projected to reach USD 85 million by 2035. Its established outpatient hematology system and early-market access mechanisms make it an important European launch market for innovative therapies. Reimbursement evidence and benefit assessment will influence how quickly new oral agents move from specialist use into broader prescribing.
United Kingdom
The United Kingdom is projected to reach USD 80 million by 2035 and grow at an 8.3% CAGR (2026-2035). NHS commissioning and technology appraisal processes create structured access pathways for high-cost therapies. These controls can preserve use of established options while maintaining a route for advanced therapies that demonstrate sufficient clinical and economic value.
France
France generated USD 32 million in 2025 and is projected to account for 4.2% of global market revenue by 2035. National reimbursement assessment remains influential in determining access to specialty ITP drugs. Demand is supported by established hematology practice and increasing treatment needs among older adult patients, while managed access mechanisms shape the adoption curve for newer agents.
Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis
Asia Pacific is projected to reach USD 340 million by 2035 and expand at a 9.5% CAGR (2026-2035). Growth reflects rising diagnostic capacity, expanding specialist care, and a large pool of patients whose treatment access is still developing. The region combines mature markets with high treatment intensity and large emerging markets where access to TPO-RAs and targeted oral therapies is broadening.
China
China generated USD 50 million in 2025 and is projected to grow at a 10.0% CAGR (2026-2035). The market benefits from a large diagnosed population, wider reimbursement inclusion, and the presence of domestically produced recombinant human thrombopoietin alongside established TPO-RA options. Regulatory development and broader urban specialist access are expanding the range of commercially treated patients.
Japan
Japan accounted for 5.0% of global market revenue in 2025 and is projected to reach USD 83 million by 2035. The country has an established hematology treatment environment, but periodic pharmaceutical price revisions constrain revenue growth relative to prescription volume. Its adoption of fostamatinib demonstrates continued interest in later-line disease management, even as supply pressure affects plasma-derived products.
India
India is projected to reach USD 59 million by 2035 and grow at a 10.4% CAGR (2026-2035). Expansion is driven by specialist-care development, improved diagnosis, and greater availability of TPO-RA options in urban centers. Generic development can widen affordability, although diagnostic infrastructure and insurance coverage will remain material constraints on conversion from disease burden to treated demand.
Australia
Australia accounted for 1.9% of global market revenue in 2025 and is projected to generate USD 32 million by 2035. It is a smaller but clinically mature market where public reimbursement decisions influence the adoption of advanced therapies. Established specialist pathways support consistent TPO-RA use, while future listings will determine uptake of newer oral treatments.
South Korea
South Korea generated USD 11 million in 2025 and is projected to grow at an 8.1% CAGR (2026-2035). The January 2025 marketing authorization for Tavalisse expanded the country's options for adults with chronic ITP who have had an inadequate response to prior therapy [7]. This approval supports a more developed sequential-treatment pathway and provides a reference point for future novel-agent reimbursement discussions.
Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis
Latin America accounted for 5.0% of global market revenue in 2025 and is projected to reach USD 85 million by 2035. Growth depends on improving specialist access, formulary inclusion of TPO-RAs, and insurance expansion across the region's larger national markets. Procurement conditions and affordability remain uneven, which favors a varied treatment mix across public and private settings.
Brazil
Brazil generated USD 18 million in 2025 and is projected to reach USD 42 million by 2035. Its scale, academic hematology centers, and combination of public and supplementary insurance create the region's strongest base for chronic-ITP treatment expansion. Greater availability of generics and biosimilars could broaden access while putting pressure on treatment pricing.
Mexico
Mexico accounted for 1.5% of global market revenue in 2025 and is projected to grow at a 9.0% CAGR (2026-2035). Its public-private healthcare structure produces differentiated access to specialty therapies, with subsidized public coverage alongside premium private channels. Regulatory convergence and formulary modernization will influence the speed at which newer therapies reach eligible patients.
Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis
Middle East & Africa is projected to account for 3.5% of global market revenue by 2035 and grow at a 6.4% CAGR (2026-2035). Demand is concentrated in countries with specialized tertiary-care capacity and funded access to high-cost medicines. Elsewhere, limited hematology infrastructure, procurement constraints, and dependence on imported plasma products restrict treatment intensity.
Saudi Arabia
Saudi Arabia accounted for 1.5% of global market revenue in 2025 and is projected to reach USD 21 million by 2035. As a major GCC healthcare market, it has specialized centers capable of managing complex chronic ITP and supporting advanced treatment use. Regulatory alignment and public healthcare investment make it an important regional entry point for novel therapies.
UAE
The UAE generated USD 7 million in 2025 and is projected to grow at a 7.2% CAGR (2026-2035). Its tertiary hospital networks and early access to innovative therapies support adoption in rare hematologic conditions. Prior authorization of rilzabrutinib signals a receptive environment for advanced ITP treatment, although market scale remains limited [2].
South Africa
South Africa is projected to generate USD 12 million by 2035 and grow at a 5.5% CAGR (2026-2035). Specialist treatment remains concentrated in private care networks, while public-sector procurement limitations constrain access to premium therapies. Reliance on imported plasma products makes IVIG supply pressure particularly consequential for acute and refractory-care pathways.
GMI Analyst View
We expect regional divergence to persist because therapeutic access is determined more by diagnosis, reimbursement, and specialist capacity than by disease prevalence alone. Asia Pacific offers the strongest catch-up opportunity, while growth across Middle East & Africa will remain concentrated in better-funded health systems.
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share & Competitive Landscape
The idiopathic thrombocytopenic purpura (ITP) therapeutics market share of the top five companies was approximately 64.0% in 2025, indicating moderate concentration across branded TPO-RAs and plasma-derived immunoglobulin suppliers. Competition is intensifying through biosimilar and generic pressure in established categories, while oral targeted therapies create new positioning opportunities in refractory disease.
Amgen held 27.8% market share in 2025, supported by Nplate's established position in persistent and chronic ITP. The company benefits from physician familiarity, broad use across eligible patient populations, and infrastructure supporting injectable therapy. Its competitive challenge is to defend established prescribing relationships as biosimilar competition and oral alternatives reshape treatment preferences.
Novartis held 18.1% market share in 2025, led by its oral TPO-RA franchise. The company retains an important position in maintenance therapy, although generic entry can affect branded revenue in selected markets. Its ianalumab development program adds a potential differentiated option following positive VAYHIT2 findings, subject to future regulatory and reimbursement progress [4].
CSL Behring held 7.2% market share in 2025 through ITP-attributed IVIG sales. Its plasma fractionation expertise and global supply capabilities remain competitive strengths in urgent and acute-care settings. However, IVIG suppliers operate within a category exposed to broader supply constraints and increasing substitution toward non-plasma-derived maintenance options [5].
Grifols and Octapharma remain significant IVIG participants, with institutional relationships in hospital and infusion settings supporting demand in acute ITP management. Their strategic position depends on plasma availability, manufacturing reliability, and the ability to sustain service levels as non-ITP demand for immunoglobulin competes for constrained supply.
Recent Industry Developments
Tavalisse receives South Korea marketing authorization - January 2025: JW Pharmaceutical Corporation received marketing authorization from South Korea's Ministry of Food and Drug Safety for Tavalisse for adults with chronic ITP who had an insufficient response to prior treatment. The approval extends the availability of SYK inhibition in the country's later-line treatment pathway [7].
FDA approves Wayrilz for ITP - August 2025: The U.S. Food and Drug Administration approved Sanofi's Wayrilz for adults with persistent or chronic ITP who have had an insufficient response to prior treatment. The authorization established the first approved BTK inhibitor option for ITP in the United States [2].
Novartis reports VAYHIT2 Phase 3 results - December 2025: Novartis presented positive VAYHIT2 Phase 3 findings for ianalumab combined with eltrombopag in previously treated primary ITP. The program could introduce an additional targeted approach to the treatment landscape if subsequent regulatory development is successful [4].
European Commission approves Wayrilz for ITP - December 2025: The European Commission granted marketing authorization for Wayrilz for adult patients with ITP who are refractory to other treatments. The decision initiates national reimbursement discussions across European markets [6].
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →